Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BDC-3042 |
| Trade Name | |
| Synonyms | BDC3042|BDC 3042 |
| Drug Descriptions |
BDC-3042 is an agonistic antibody that targets Dectin-2 (CLEC6A) to induce a pro-inflammatory immune response, potentially resulting in decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 2964). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BDC-3042 | BDC-3042 | 0 | 1 |
| BDC-3042 + Pembrolizumab | BDC-3042 Pembrolizumab | 0 | 1 |